Avalo Adds Dr. Rita Jain to Board as LOTUS Trial Advances
Earlier on Wednesday, Avalo Therapeutics, Inc. (NASDAQ:AVTX) appointed Rita Jain, M.D., to its Board of Directors. Dr Jain, who previously served as Executive Vice President and Chief Medical Officer at ChemoCentryx, joins the board at the company's crucial time and plans to advance the Phase 2 LOTUS trial in HS, with results expected in mid-2026.
A chemist in a laboratory analyzing data from the various therapeutic tests conducted.
H.C. Wainwright analysts have upgraded Avalo Therapeutics, Inc. (NASDAQ:AVTX) to Buy from Neutral, while setting the 12-month price target to $15.00, implying an upside of over 200%. The leading candidate, AVTX-009, is what the analysts believe will lead the future of the company. The firm highlights that the mechanism represents an optimal strategy, stating that the competitor data reinforces the effectiveness of this risk-mitigated approach in treating the condition.
Avalo Therapeutics, Inc. (NASDAQ:AVTX), incorporated in 2001, operates as a clinical-stage biotechnology company that develops treatments for immune dysregulation in the United States. The core offering of this Maryland-based company is AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß.
While we acknowledge the potential of AVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Qualys (QLYS) Wins Two Pwnie Awards at DEF CON for Groundbreaking OpenSSH Vulnerability Research
Qualys, Inc. (NASDAQ:QLYS) is one of the Qualys, Inc. (NASDAQ:QLYS) is one of the best midcap AI stocks to buy right now. On August 12, 2025, Qualys announced that its Threat Research Unit (TRU) received two Pwnie Awards at the DEF CON cybersecurity conference for its groundbreaking work uncovering critical OpenSSH vulnerabilities. The awards, 'Epic Achievement' and 'Best Remote Code Execution (RCE)', recognized Qualys for identifying CVE-2024-6387, the first pre-authentication RCE in OpenSSH in nearly two decades, and CVE-2025-26465, a man-in-the-middle attack affecting FreeBSD clients. The wins cement Qualys' status as a major player in vulnerability research. welcomia/ Alongside its ongoing threat research, Qualys expanded coverage within its Enterprise TruRisk Platform on August 12, 2025, issuing new vulnerability checks tied to Microsoft's latest Patch Tuesday update. While the company did not publish a formal press release, its research portal listed 98 vulnerabilities across 12 Microsoft security bulletins, with immediate support deployed for customer environments. The update underscores Qualys' operational emphasis on rapid detection and remediation, reinforcing its reputation for delivering same-day protections aligned with major vendor disclosures. Qualys is a U.S.-based provider of cloud-native IT, security, and compliance solutions. Its platform is used by global enterprises to manage vulnerabilities, ensure policy compliance, protect against threats, and inventory digital assets across hybrid environments. While we acknowledge the potential of QLYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
SentinelOne (S) Expands Mimecast Partnership to Advance Human-Centric Cybersecurity
SentinelOne, Inc. (NYSE:S is one of the SentinelOne, Inc. (NYSE:S) is one of the best midcap AI stocks to buy right now. On August 6, 2025, SentinelOne announced an expanded partnership with Mimecast to advance human-centric cybersecurity. The integration connects SentinelOne's Singularity™ Platform with Mimecast's Human Risk Management (HRM) solution, enabling enterprises to correlate endpoint telemetry with behavioral insights and email-based threat intelligence. The goal is to strengthen real-time detection, automate risk scoring, and deliver targeted awareness training based on individual user behavior. Den Rise/ This collaboration marks a shift toward more adaptive, user-aware security frameworks. By analyzing how people interact with their environments, through devices, apps, and communications, the combined solution helps identify at-risk users and prioritize them for intervention. SentinelOne's AI-driven endpoint protection feeds into Mimecast's analytics to uncover patterns of risky behavior, enhancing both detection and prevention efforts. SentinelOne is a California-based cybersecurity company that provides autonomous endpoint protection, cloud security, and identity threat detection through its Singularity™ Platform. The company employs artificial intelligence and machine learning to deliver real-time threat prevention, detection, and response at machine speed. While we acknowledge the potential of S as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and .
Yahoo
7 hours ago
- Yahoo
Globant (GLOB) Upgrades GEAI Platform with New Protocols to Drive Cross-Platform AI Interoperability
Globant S.A. (NYSE:GLOB) is one of the Globant S.A. (NYSE:GLOB) is one of the best midcap AI stocks to buy right now. On July 31, 2025, Globant unveiled a major upgrade to its Globant Enterprise AI (GEAI) platform, now incorporating Model Context Protocol (MCP) and Agent2Agent (A2A) Protocol capabilities. This update allows seamless interoperability between GEAI and external AI frameworks — from Agentforce and Google Cloud to Azure AI Foundry and Amazon Bedrock — making GEAI a more flexible and integrative foundation for enterprise AI. Copyright: photovibes / 123RF Stock Photo The enhancement boosts enterprises' ability to collaborate across AI systems more fluidly and modernize legacy systems with greater efficiency. By enabling platform-agnostic communication, developers can mix and match models while reducing integration friction. This positions Globant not just as a service provider, but as a connective fabric across complex AI ecosystems. Globant is a Luxembourg-based digital technology company with a core focus on reinvention through AI-powered software solutions. Its end-to-end platform supports everything from agile teams to enterprise-grade AI deployments, helping global clients in sectors like media, tech, and finance bring innovative products to life. While we acknowledge the potential of GLOB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and .
